TICKERNERD
Menu
ETONETONHealthcare · Drug Manufacturers - Specialty & Generic

ETON Stock Forecast: Eton Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$63
+5.94% on the day

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. hold a median 12-month price target of $70 — +10.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
99 / 100
Median analyst target
$70
Analysts covering
4
Total return, dividends reinvested
1W
+7.8%
1M
+46.9%
YTD
+275.3%
1Y
+271.4%
From 52W high
0.0%
From 52W low
+342.3%
$14
$63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ETON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eton Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Revisions
95
Value
93
Quality
88
Volatility
87
Growth
86
Issuance
64
Accruals
42
Size
38

Momentum (100): The shares have been drifting up relative to others.

Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ETON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ETON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26ETONHigh $76Median $70Low $68

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $68Median $70High $76

The green dot is the last close — the median target sits +10.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $70
14 Aug 2026Canaccord GenuityMaintainsBuy$60 → $68
14 Aug 2026HC Wainwright & Co.MaintainsBuy$65 → $70
11 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $65
28 July 2026Craig-HallumMaintainsBuy$40 → $62
28 July 2026Craig-HallumMaintainsBuy—
17 July 2026Canaccord GenuityInitiatesBuy$60
17 July 2026Canaccord GenuityInitiatesBuy—
15 May 2026HC Wainwright & Co.MaintainsBuy$52 → $57
15 May 2026HC Wainwright & Co.MaintainsBuy—
20 Mar 2026B. Riley SecuritiesMaintainsBuy—
20 Mar 2026Craig-HallumMaintainsBuy—
20 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026Craig-HallumMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
29 May 2025HC Wainwright & Co.MaintainsBuy—
16 May 2025B. Riley SecuritiesReiteratesBuy—
14 May 2025Craig-HallumMaintainsBuy—
19 Mar 2025B. Riley SecuritiesReiteratesBuy—
19 Mar 2025Craig-HallumMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ETON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ETON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+38.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

Eton Pharmaceuticals, Inc. (ETON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
162.7×

Cheaper than 4% of US stocks

Price / sales
17.2×

Cheaper than 10% of US stocks

Price / book
38.5×

Cheaper than 3% of US stocks

EV / EBITDA
72.1×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
98.6%

Higher than 93% of US stocks

Earnings growth (YoY)
40.4%

Higher than 71% of US stocks

Gross margin
60.7%

Higher than 74% of US stocks

Operating margin
35.8%

Higher than 90% of US stocks

Net margin
12.0%

Higher than 74% of US stocks

Returns & dividend
Return on equity
36.0%

Higher than 90% of US stocks

Return on assets
11.9%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ETON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ETONEton Pharmaceuticals, Inc.$1.8B
99
ALVOAlvotech$1.7B
26
ANIPANI Pharmaceuticals, Inc.$1.7B
95
PRGOPerrigo Co. Plc$2.0B
69
TRLVTrulieve Cannabis Corp.$2.1B
88
HROWHarrow, Inc.$1.5B
49
PAHCPhibro Animal Health Corp.$1.5B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eton Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ETON news & analysis

Three Biotech Stocks Stick Out With Their Stellar Charts

Investors Business Daily · 21 Aug 2026positive

A news item highlights three biotech stocks, each of which rose after recent earnings reports and has outperformed 97% of stocks over the past 12 months, with Eton Pharmaceuticals included among them based on its strong chart performance.

Why it matters — For Eton Pharmaceuticals watchers, the item signals that ETON is being recognized among top-performing biotech stocks with notable relative strength.

Why Eton Pharmaceuticals Is Top of the Class Today

The Motley Fool · 14 Aug 2026positive

Eton Pharmaceuticals reported quarterly results that exceeded expectations on both revenue and earnings. Management also announced it is licensing a new drug and raised its financial guidance through the end of 2026.

Why it matters — A beat on earnings, a new licensing deal, and higher forward guidance collectively signal strengthening business momentum for the company.

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Seeking Alpha · 14 Aug 2026positive

Eton Pharmaceuticals reported record Q2 2026 results, with product sales doubling year-over-year, and raised its full-year revenue guidance to over $145 million. The company outlined plans to exceed $500 million in peak annual sales through organic growth, pipeline development, and acquisitions in rare disease markets.

Why it matters — A shareholder would care because the company is projecting significant margin expansion, with adjusted EBITDA margins expected to exceed 35% in 2026 and gross margins rising above 75%.

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High

Investors Business Daily · 14 Aug 2026positive

Eton Pharmaceuticals shares hit a record high after the company reported second-quarter sales that significantly exceeded expectations and raised its full-year guidance.

Why it matters — The strong quarterly results and upward revision to guidance signal better-than-expected business performance, which is a key indicator for investors tracking the company's commercial progress.

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Eton Pharmaceuticals' Q2 2026 earnings call. The item is a transcript of the company's quarterly earnings discussion.

Why it matters — ETON watchers would care because the transcript provides the full detail of management's remarks on the company's Q2 2026 results and outlook.

FAQ

Frequently asked questions about ETON stock

What is the ETON stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. have a median 12-month price target of $70, with estimates ranging from $68 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ETON stock a buy right now?

Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ETON?

As at 22 Aug 2026, Eton Pharmaceuticals, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will ETON stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +10.3% from the last close, and Ticker Nerd's factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ETON stock forecast for 2030?

No analyst covering Eton Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ETON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $68 to $76 over the next 12 months.

How has ETON stock performed over the past year?

Eton Pharmaceuticals, Inc. returned +271.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eton Pharmaceuticals, Inc. do?

Eton Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases, with particular focus on pediatric endocrinology and metabolic disorders.

What is the latest news on ETON?

The most recent item we track (Investors Business Daily, 21 Aug 2026): "Three Biotech Stocks Stick Out With Their Stellar Charts". A news item highlights three biotech stocks, each of which rose after recent earnings reports and has outperformed 97% of stocks over the past 12 months, with Eton Pharmaceuticals included among them based on its strong chart performance.

Company

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases, with particular focus on pediatric endocrinology and metabolic disorders. The company maintains a growing portfolio of FDA-approved commercial products including Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle for adrenal insufficiency, Khindivi for adrenocortical insufficiency, Galzin for Wilson disease, PKU Golike for phenylketonuria, and several other rare disease medications. Eton's business model centers on acquiring and developing ultra-rare disease treatments that larger pharmaceutical companies find commercially impractical, supported by a specialized sales force and comprehensive patient support programs including zero co-pay options for eligible patients. The company's late-stage pipeline includes candidates such as ET-600 for diabetes insipidus and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton's strategy emphasizes delivering treatments to underserved patient populations with conditions affecting small numbers of individuals, positioning itself as a leader in the orphan drug market segment. Headquartered in Deer Park, Illinois, Eton serves patients through direct commercialization and partnerships with specialty pharmacy providers.

CEO Mr. Sean E. Brynjelsen · 44 employees · United States · https://www.etonpharma.com